Mayo Clin Proc, May 2003, Vol 78 BCNU-Associated Pulmonary Fibrosis 631 Figure 1. Chest radiograph of BCNU-treated patient, showing small right apical
|
|
- Evan Bradford
- 6 years ago
- Views:
Transcription
1 630 Case Report Upper Lobe Pulmonary Fibrosis Associated With High-Dose Chemotherapy Containing BCNU for Bone Marrow Transplantation JAMES M. PARISH, MD; JOHN R. MUHM, MD; AND KEVIN O. LESLIE, MD Upper lobe fibrotic lung disease is most often associated with sarcoidosis, Langerhans cell histiocytosis, silicosis, and other pneumoconioses but is usually not associated with drug-induced lung disease. Carmustine (BCNU) is a chemotherapeutic agent known to cause pulmonary toxicity. The radiographic pattern is usually diffuse bilateral lung disease predominantly in the lung bases. Upper lobe fibrotic disease associated with BCNU has been reported to occur in children treated for central nervous system gliomas. Often the lung disease occurs years after the exposure. Despite the widespread use of BCNU in the treatment of malignancy in adults, to our knowledge, the complication of upper lobe fibrotic disease has not been reported in adults. We describe a patient who presented with pneumothorax and bilateral upper lobe pulmonary fibrosis that we believe was due to BCNU given for bone marrow transplantation as part of therapy for breast cancer. Bilateral upper lobe pulmonary fibrosis can be associated with chemotherapeutic drugs. Mayo Clin Proc. 2003;78: CT = computed tomography; DLCO = diffusing capacity of the lung for carbon monoxide; FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity More than 10 years ago, O Driscoll et al 1 described a group of patients treated with carmustine (BCNU) for central nervous system gliomas during childhood who developed upper lobe pulmonary fibrosis years after therapy. To our knowledge, bilateral upper lobe fibrotic lung disease has not been reported in adults receiving BCNU. 2 High-dose chemotherapy, which often includes BCNU, before bone marrow transplantation is known to produce pulmonary toxicity in adults, but the typical pattern is bilateral diffuse disease, predominantly in the lower lung zones and occurring weeks to months after therapy is administered. 3 We report a case of BCNU pulmonary toxicity presenting as progressive bilateral upper lobe pulmonary fibrosis in an adult who had received high-dose chemotherapy, including BCNU, preceding bone marrow transplantation for advanced breast cancer. REPORT OF A CASE A 57-year-old woman was referred to our institutuion for pulmonary consultation. She had experienced progressive dyspnea and cough for about 2 years, but her symptoms had become substantially worse during the 3 months before consultation. She had a 20-pack-year history of cigarette smoking but had quit smoking 17 years previously. She had no history of chronic obstructive pulmonary disease. From the Division of Pulmonary Medicine (J.M.P.), Department of Diagnostic Radiology (J.R.M.), and Department of Laboratory Medicine/Pathology (K.O.L.), Mayo Clinic, Scottsdale, Ariz. Address reprint requests and correspondence to James M. Parish, MD, Division of Pulmonary Medicine, Mayo Clinic, Shea Blvd, Scottsdale, AZ Four years before referral, she was diagnosed as having stage IIB breast cancer. She underwent local excision and radiation therapy localized to the left breast, left axilla, and left supraclavicular area. Over the next 3 months, she received 4 courses of doxorubicin (60 mg/ m 2 ) and cyclophosphamide (1200 mg/m 2 ). Four months after her initial diagnosis of breast cancer, she received high-dose chemotherapy preceding bone marrow stem cell transplantation. The chemotherapeutic regimen included 3 doses of cyclophosphamide (1875 mg/m 2 ), 3 doses of cisplatin (55 mg/m 2 ), and 1 dose of carmustine (450 mg/ m 2 ). She received methylprednisolone (1 mg/kg) for 7 days before bone marrow transplantation. Total body irradiation was not administered. Before transplantation, pulmonary function test results were normal, and computed tomography (CT) of the thorax showed no evidence of parenchymal disease. No pulmonary complications occurred during transplantation. On physical examination at our institution, the patient had no clinical evidence of recurrent breast cancer. Bronchial breath sounds were present in the upper lobes both anteriorly and posteriorly, but the lungs were otherwise clear on auscultation. Cardiovascular examination was notable only for tachycardia. The patient had no clubbing, cyanosis, edema, abnormal skin lesions, or abnormal lymphadenopathy. The remainder of the physical examination findings were unremarkable. Pulmonary function studies showed a restrictive pattern, with a total lung capacity of 3.6 L (71% of predicted), forced vital capacity (FVC) of 1.71 L (53% of predicted), forced expiratory volume in 1 second (FEV 1 ) of 1.62 L Mayo Clin Proc. 2003;78: Mayo Foundation for Medical Education and Research
2 Mayo Clin Proc, May 2003, Vol 78 BCNU-Associated Pulmonary Fibrosis 631 Figure 1. Chest radiograph of BCNU-treated patient, showing small right apical pneumothorax, bilateral apical pleural thickening, bilateral upper lobe fibrosis, and upward retraction of both hila. The pneumothorax was not evident on a radiograph obtained 1 year earlier. (62% of predicted), FEV 1 /FVC ratio of 94%, and diffusing capacity of the lung for carbon monoxide (DLCO) of 8.7 ml min 1 mm Hg 1 (39% of predicted). Chest radiography (Figure 1) showed a small right apical pneumothorax that was not evident on a radiograph obtained 1 year earlier. Bilateral apical pleural thickening, bilateral upper lobe fibrosis, and upward retraction of both hila were also noted. Thorax CT showed bilateral apical pleural thickening, bilateral upper lobe subpleural fibrosis, and a small, partially loculated right apical pneumothorax (Figure 2, top), multiple small subpleural bullae in the right apex (Figure 2, middle), and a small right pleural effusion (Figure 2, bottom). Aspiration was initially unsuccessful in resolving the pneumothorax. After several weeks of observation, the pneumothorax resolved, but the patient had persistent dyspnea and coughing. Bronchoscopy, cultures of bronchial washings, and transbronchoscopic lung biopsy were performed, but results were nondiagnostic. To establish a definite diagnosis, a thoracoscopic lung biopsy was performed. Microscopic evaluation of the wedge biopsy specimen revealed a distinctive pattern of pleural and subpleural parenchymal fibrosis (Figure 3, upper left). The pleural fibrosis appeared denser and less fibroblastic than that seen subpleurally and in other involved parenchymal areas (Figure 3, upper right). Fibrosis extended into the underlying lung tissue, following interlobular septae (Figure 3, lower left) with relative centrilobular sparing. Peribronchiolar fibrosis associated with mild bronchiolectasis and patchy mucostasis was also noted (Figure 3, lower right). Mild chronic parenchymal inflammation consisting of lymphocytes and scattered eosinophils was present, mainly in association with areas of fibrosis. The radiographic and microscopic findings lacked specific features of the diseases proposed in the clinical differential diagnosis (Langerhans cell histiocytosis, sarcoidosis, pneumoconioses, and granulomatous infections) and were most consistent with drug toxicity. Corticosteriods were administered, but dyspnea, cough, and exercise tolerance worsened over the course of the next year. Thorax CT showed resolution of the right apical lobe pneumothorax and progression of the bilateral apical pleural thickening and bilateral interstitial fibrosis (Figure 4). The patient s dyspnea and pulmonary function worsened further over the ensuing 2 years. Azathioprine was administered with no apparent clinical improvement. Lung transplantation was considered, but the patient developed a severe respiratory infection and died before the procedure could be performed. DISCUSSION Alkylating agents such as BCNU (part of the nitrosourea group) have been used for decades as chemotherapy for neoplastic disease. The most important action of the alkylating agents is disturbance of the fundamental mechanism of cell proliferation, DNA synthesis and cell division. BCNU was introduced for investigational clinical research in 1964 and became available commercially for clinical use in Initial experience with the drug identified myelosuppression and emesis as the major adverse effects, with mild hepatic and renal toxicities occurring less frequently. 5 Both BCNU and CCNU (lomustine) are highly lipophilic, allowing them to cross the blood-brain barrier. This property makes them important in the treatment of malignant brain tumors such as astrocytomas and metastatic tumors involving the brain. The nitrosoureas are also used in the treatment of Hodgkin disease and lymphomas. The first case of BCNU pulmonary toxicity in humans was reported by Holoye et al 6 in Durant et al 4 described 10 patients who developed pulmonary toxicity after BCNU therapy for malignancy, 9 of whom had also received cyclophosphamide, another drug known to be associated with pulmonary toxicity. In a report by Selker et al, 7 14 of 47 patients who had undergone chemotherapy, including BCNU, for primary intracranial glioma developed pulmonary toxicity, suggesting a prevalence of BCNU-related pulmonary toxicity as high as 30%. The exact mechanism of BCNU pulmonary toxicity is unknown, but several studies have noted a relationship between the dose of BCNU and this adverse reaction. 5,8 Weiss et al 5 found that a cumulative dose of 1200 to 1500 mg/m 2 significantly increased the risk of pulmonary toxicity. Other significant risk factors included preexisting lung disease, thoracic irradiation, concomitant administration of other drugs with known pulmonary toxicity, and exposure to high fractions of inspired oxygen.
3 632 Figure 2. Computed tomographic scans of the thorax in BCNUtreated patient, showing a small right apical pneumothorax, bilateral apical pleural thickening, and bilateral upper lobe subpleural fibrosis (top), multiple small right apical subpleural bullae (middle), and a small right pleural effusion (bottom). High-dose chemotherapy followed by autologous bone marrow transplantion has been used frequently in the past decade for the treatment of solid tumors and hematologic malignancies. A single high dose of BCNU has often been used in these regimens. Seiden et al 9 found that pulmonary toxicity occurred more commonly with chemotherapeutic protocols containing BCNU than with protocols that did not include this drug. A protocol containing both BCNU and cyclophosphamide had the highest prevalence of interstitial pneumonitis, defined by significant reductions in FEV 1 and DLCO. Ager et a 10 observed that high-dose chemotherapeutic regimens preceding autologous stem cell transplantation were associated with a 58% prevalence of pulmonary toxicity (identified by DLCO reductions of 20%) if the dose of BCNU was 600 mg/m 2 or higher compared with a prevalence of 8% with a 450-mg/m 2 dose. Chemotherapeutic regimens including high-dose BCNU can be associated with asymptomatic and subclinical decreases in DLCO that most likely represent a manifestation of pulmonary toxicity. Rubio et al 11 found that one of the main risk factors for idiopathic pneumonia syndrome in patients receiving high-dose chemotherapy for Hodgkin disease was a dose of BCNU greater than 475 mg/m 2. Frequently, treatment with corticosteroids can reverse this BCNU-associated decrease in DLCO. 12 In these reports of high-dose BCNU associated lung toxicity, diffuse interstitial infiltrates were observed most frequently. However, bilateral upper lobe fibrosis, as seen in our patient, has not been reported previously. Wilczynski et al 13 described a delayed pulmonary toxicity syndrome characterized by cough, dyspnea, and decreased DLCO (50%-60% of baseline) after high-dose chemotherapy (cyclophosphamide, cisplatin, BCNU) and autologous bone marrow transplantation. The mean onset of symptoms occurred 10.3 weeks after bone marrow transplantation, and the patients often responded to corticosteroid therapy. No relationship to BCNU dose was identified in these patients, suggesting that other factors were more relevant for development of pulmonary toxicity. Todd et al 14 reported pulmonary toxicity in patients with breast cancer who were treated with chemotherapy and bone marrow transplantation. In that study, 10 of 23 patients with pulmonary toxicity had open-lung or transbronchoscopic lung biopsies. The mean onset of symptoms was 48 weeks after induction chemotherapy. Three of the 10 patients died within 6 months, and 7 recovered with corticosteroid therapy within 8 months to 2 years. Five of the patients had upper lobe and lower lobe pulmonary interstitial abnormalities. In adults who had delayed-onset pulmonary toxicity after high-dose chemotherapy in association with autologous bone marrow transplantation, CT findings were predominantly peripheral, ground-glass, or consolidated opacities that occasionally appeared nodular or masslike. Occasionally, the CT pattern was suggestive of pulmonary edema with hazy opacification of the dependent portions of the lung with engorgement of the vessels and subpleural septal thicken-
4 Mayo Clin Proc, May 2003, Vol 78 BCNU-Associated Pulmonary Fibrosis 633 Figure 3. Photomicrographs of lung biopsy specimen from BCNU-treated patient. Upper left, Pleural and interlobular septal fibrosis with portions of the intervening parenchyma relatively spared. Delicate interstitial fibrosis is present to a variable degree throughout the sections. Some tractional dilatation of membranous bronchioles is evident. Upper right, High-magnification view showing laminated appearance of denser peripheral fibrosis interfacing with looser fibrosis beneath. P = pleural surface. Lower left, High-magnification view showing parenchymal fibrosis with associated mild chronic inflammation. Lower right, Cystic membranous bronchiole adjacent to area of fibrosis (hematoxylin-eosin, original magnification: upper left, 20; upper right, 40; lower left, 60; lower right, 40). ing. 2 Pleural effusions and adenopathy were uncommon. Bilateral upper lobe pulmonary fibrosis was not reported in these cases of idiopathic or delayed pulmonary toxicity after bone marrrow transplantation. In all these studies describing BCNU-associated pulmonary toxicity, radiographic abnormalities due to pulmonary fibrosis are typically described as diffuse and bilateral, involving predominantly the lower lobes. A review of adult patients with drug-induced lung disease associated with bleomycin, nitrofurantoin, penicillamine, BCNU, and amiodarone described 4 frequently observed patterns of lung disease: (1) fibrosis with or without consolidation, (2) ground-glass opacities, (3) widespread bilateral consolidation, and (4) bronchial wall thickening. 3 Upper lobe pulmonary fibrosis was not described. In contrast to the pattern of BCNU pulmonary toxicity described in adults, O Driscoll et al 1 described a distinctly different pattern of upper lobe pulmonary fibrosis in children. These investigators reported pulmonary fibrosis occurring up to 17 years after treatment with BCNU for brain tumors. Of 31 patients, 14 died of their tumor, but 6 died of pulmonary fibrosis. Of 8 survivors available for study, 6 had abnormal chest radiographic findings and chest CT scans that showed predominantly upper-zone pulmonary fibrosis. The pattern was patchy linear opacities with upward retraction of the pulmonary hila, a pattern that had not been described previously. Two patients had normal findings on chest radiography despite restrictive spirometry and histologic evidence of fibrosis. Taylor et al 15 reported upper lobe subpleural abnormalities in the same group of
5 634 Figure 4. Computed tomographic scans of the thorax in BCNU-treated patient 1 year after presentation, showing resolution of the right apical pneumothorax (left) and progression of the bilateral apical pleural thickening, bilateral subpleural fibrosis, and bilateral upper lobe fibrosis (left and right). patients studied by O Driscoll et al, 1 including one patient with bilateral spontaneous pneumothorax. Histologic changes included focal interstitial fibrosis and elastosis, prominent fibroblasts, and a focal lymphocytic infiltration. 16 One important difference between the children with upper lobe pulmonary fibrosis described by O Driscoll et al 1 and patients receiving conditioning regimens for bone marrow transplantation is the dose and frequency of the administration of BCNU. Patients undergoing high-dose chemotherapy before bone marrow transplantation typically receive a single dose of BCNU, whereas the patients reported by O Driscoll et al received BCNU at 100 mg/m 2 every 6 to 8 weeks for up to 2 years. Our patient received a single high dose of BCNU before bone marrow transplantation, rather than intermittent lower doses. In summary, delayed onset of upper lobe pulmonary fibrosis associated with BCNU therapy has been described in children treated for gliomas and occurs years after therapy. Pulmonary toxicity is commonly observed in adults after BCNU and high-dose chemotherapy, but to our knowledge, upper lobe pulmonary fibrosis has not been described in adults. The occurrence of upper lobe pulmonary fibrosis in adults is generally associated with sarcoidosis, Langerhans cell histiocytosis, silicosis, berylliosis, or other pneumoconioses. It can be progressive, unresponsive to treatment, and fatal. REFERENCES 1. O Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990;323: Patz EF Jr, Peters WP, Goodman PC. Pulmonary drug toxicity following high-dose chemotherapy with autologous bone marrow transplantation: CT findings in 20 cases. J Thorac Imaging. 1994;9: Padley SP, Adler B, Hansell DM, Muller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol. 1992;46: Durant JR, Norgard MJ, Murad TM, Bartolucci AA, Langford KH. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med. 1979;90: Weiss RB, Poster DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev. 1981;8: Holoye PY, Jenkins DE, Greenberg SD. Pulmonary toxicity in long-term administration of BCNU. Cancer Treat Rep. 1976;60: Selker RG, Jacobs SA, Moore PB, et al. 1,3-Bis(2-chloroethyl)-1- nitrosourea (BCNU)-induced pulmonary fibrosis. Neurosurgery. 1980;7: Weinstein AS, Diener-West M, Nelson DF, Pakuris E. Pulmonary toxicity of carmustine in patients treated for malignant glioma. Cancer Treat Rep. 1986;70: Seiden MV, Elias A, Ayash L, et al. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant. 1992;10: Ager S, Mahendra P, Richards EM, Bass G, Baglin TP, Marcus RE. High-dose carmustine, etoposide and melphalan ( BEM ) with autologous stem cell transplantation: a dose-toxicity study. Bone Marrow Transplant. 1996;17: Rubio C, Hill ME, Milan S, O Brien ME, Cunningham D. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin s disease. Br J Cancer. 1997;75: Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest. 1995;107: Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med. 1998;157: Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis. 1993;147: Taylor PM, O Driscoll BR, Gattamaneni HR, Woodcock AA. Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features. Clin Radiol. 1991;44: Hasleton PS, O Driscoll BR, Lynch P, et al. Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. J Pathol. 1991;164:31-36.
4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationSeptember 2014 Imaging Case of the Month. Michael B. Gotway, MD. Department of Radiology Mayo Clinic Arizona Scottsdale, AZ
September 2014 Imaging Case of the Month Michael B. Gotway, MD Department of Radiology Mayo Clinic Arizona Scottsdale, AZ Clinical History: A 57-year-old non-smoking woman presented to her physician as
More informationHRCT in Diffuse Interstitial Lung Disease Steps in High Resolution CT Diagnosis. Where are the lymphatics? Anatomic distribution
Steps in High Resolution CT Diagnosis Pattern of abnormality Distribution of disease Associated findings Clinical history Tomás Franquet MD What is the diagnosis? Hospital de Sant Pau. Barcelona Secondary
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationCryptogenic Organizing Pneumonia Diagnosis Approach Based on a Clinical-Radiologic-Pathologic Consensus
Cryptogenic Organizing Pneumonia Diagnosis Approach Based on a Clinical-Radiologic-Pathologic Consensus Poster No.: C-1622 Congress: ECR 2012 Type: Scientific Exhibit Authors: C. Cordero Lares, E. Zorita
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationSystemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
More informationSESSION IV: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS PULMONARY PATHOLOGY I. December 5, 2012
SESSION IV: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS PULMONARY PATHOLOGY I December 5, 2012 FACULTY COPY GOAL: Describe the basic morphologic and pathophysiologic changes in various conditions
More informationAcute and Chronic Lung Disease
KATHOLIEKE UNIVERSITEIT LEUVEN Faculty of Medicine Acute and Chronic Lung Disease W De Wever, JA Verschakelen Department of Radiology, University Hospitals Leuven, Belgium Clinical utility of HRCT To detect
More informationAugust 2018 Imaging Case of the Month: Dyspnea in a 55-Year-Old Smoker. Michael B. Gotway, MD
August 2018 Imaging Case of the Month: Dyspnea in a 55-Year-Old Smoker Michael B. Gotway, MD Department of Radiology Mayo Clinic Arizona Scottsdale, AZ USA Clinical History: A 55 year old woman presented
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationJune 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference. Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2
June 2013 Pulmonary Case of the Month: Diagnosis Makes a Difference Lewis J. Wesselius, MD 1 Henry D. Tazelaar, MD 2 Departments of Pulmonary Medicine 1 and Laboratory Medicine and Pathology 2 Mayo Clinic
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationARTICLE IN PRESS. Ahuva Grubstein a, Daniele Bendayan b, Ithak Schactman c, Maya Cohen a, David Shitrit b, Mordechai R. Kramer b,
Respiratory Medicine (2005) 99, 948 954 Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature
More informationRadiation Pneumonitis Joseph Junewick, MD FACR
Radiation Pneumonitis Joseph Junewick, MD FACR 03/19/2010 History 16 year old with history of relapsed stage IV-A Hodgkin disease. Prior pulmonary involvement was irradiated. Diagnosis Radiation Pneumonitis
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationRadiological Imaging of Drug-Induced Pulmonary Lesions
Review Article imedpub Journals www.imedpub.com Journal of Clinical Radiology and Case Reports Radiological Imaging of Drug-Induced Pulmonary Lesions D souza M *, Rajiah P, Khan A and Irion K Department
More informationLung Allograft Dysfunction
Lung Allograft Dysfunction Carlos S. Restrepo M.D. Ameya Baxi M.D. Department of Radiology University of Texas Health San Antonio Disclaimer: We do not have any conflict of interest or financial gain to
More informationCombined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases
CASE REPORT Combined Unclassifiable Interstitial Pneumonia and Emphysema: A Report of Two Cases Nobuhiko Nagata 1, Kentaro Watanabe 2, Michihiro Yoshimi 3, Hiroshi Okabayashi 4, Katsuo Sueishi 5, Kentaro
More informationThoracic lung involvement in rheumatoid arthritis: Findings on HRCT
Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT Poster No.: C-2488 Congress: ECR 2015 Type: Educational Exhibit Authors: R. E. Correa Soto, M. J. Martín Sánchez, J. M. Fernandez 1 1
More informationInteresting Cases. Pulmonary
Interesting Cases Pulmonary 54M with prior history of COPD, hep B/C, and possible history of TB presented with acute on chronic dyspnea, and productive cough Hazy opacity overlying the left hemithorax
More informationRadiologic findings of drug-induced lung disease
Radiologic findings of drug-induced lung disease Poster No.: P-0115 Congress: ESTI 2015 Type: Educational Poster Authors: A. I. C. Santos, A. F. Roque, R. Mamede, L. Oliveira, T. Saldanha; Lisbon/PT Keywords:
More informationCommon things are common, but not always the answer
Kevin Conroy, Joe Mackenzie, Stephen Cowie kevin.conroy@nhs.net Respiratory Dept, Darlington Memorial Hospital, Darlington, UK. Common things are common, but not always the answer Case report Cite as:
More informationPULMONARY MEDICINE BOARD REVIEW. Financial Conflicts of Interest. Question #1: Question #1 (Cont.): None. Christopher H. Fanta, M.D.
PULMONARY MEDICINE BOARD REVIEW Christopher H. Fanta, M.D. Pulmonary and Critical Care Division Brigham and Women s Hospital Partners Asthma Center Harvard Medical School Financial Conflicts of Interest
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationSmoking-related Interstitial Lung Diseases: High-Resolution CT Findings
Smoking-related Interstitial Lung Diseases: High-Resolution CT Findings Poster No.: C-2358 Congress: ECR 2013 Type: Educational Exhibit Authors: V. Cuartero Revilla, M. Nogueras Carrasco, P. Olmedilla
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationImaging findings in Hypersensitivity Pneumonitis - a pictorical review.
Imaging findings in Hypersensitivity Pneumonitis - a pictorical review. Poster No.: C-1655 Congress: ECR 2014 Type: Educational Exhibit Authors: B. M. Araujo, A. F. S. Simões, M. S. C. Rodrigues, J. Pereira;
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationINTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
More informationOctober 2012 Imaging Case of the Month. Michael B. Gotway, MD Associate Editor Imaging. Department of Radiology Mayo Clinic Arizona Scottsdale, AZ
October 2012 Imaging Case of the Month Michael B. Gotway, MD Associate Editor Imaging Department of Radiology Mayo Clinic Arizona Scottsdale, AZ Clinical History: A 65-year-old non-smoking woman presented
More informationHYPERSENSITIVITY PNEUMONITIS
HYPERSENSITIVITY PNEUMONITIS A preventable fibrosis MOSAVIR ANSARIE MB., FCCP INTERSTITIAL LUNG DISEASES A heterogeneous group of non infectious, non malignant diffuse parenchymal disorders of the lower
More informationARDS - a must know. Page 1 of 14
ARDS - a must know Poster No.: C-1683 Congress: ECR 2016 Type: Authors: Keywords: DOI: Educational Exhibit M. Cristian; Turda/RO Education and training, Edema, Acute, Localisation, Education, Digital radiography,
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationHow to Analyse Difficult Chest CT
How to Analyse Difficult Chest CT Complex diseases are:- - Large lesion - Unusual or atypical pattern - Multiple discordant findings Diffuse diseases are:- - Numerous findings in both sides 3 basic steps
More informationPleuroparenchymal fibroelastosis as a late complication of chemotherapy agents
ERJ Express. Published on May 2, 2014 as doi: 10.1183/09031936.00214713 LETTER IN PRESS CORRECTED PROOF Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents To the Editor: We
More informationPulmonary fibrosis on the lateral chest radiograph: Kerley D lines revisited
Insights Imaging (2017) 8:483 489 DOI 10.1007/s13244-017-0565-2 PICTORIAL REVIEW Pulmonary fibrosis on the lateral chest radiograph: Kerley D lines revisited Daniel B. Green 1 & Alan C. Legasto 1 & Ian
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationPulmonary Complications of Antineoplastic Agents : Era of Targeted Therapy
Pulmonary Complications of Antineoplastic Agents : Era of Targeted Therapy Poster No.: C-1230 Congress: ECR 2013 Type: Educational Exhibit Authors: H. Y. Kim, J. H. Hwang, Y.-W. Chang, J. Y. Moon; Seoul/KR
More informationKey words: CT scanners; interstitial lung diseases; polymyositis-dermatomyositis; x-ray
Nonspecific Interstitial Pneumonia Associated With Polymyositis and Dermatomyositis* Serial High-Resolution CT Findings and Functional Correlation Hiroaki Arakawa, MD; Hidehiro Yamada, MD; Yasuyuki Kurihara,
More informationPulmonary changes induced by radiotherapy. HRCT findings
Pulmonary changes induced by radiotherapy. HRCT findings Poster No.: C-2299 Congress: ECR 2015 Type: Educational Exhibit Authors: R. E. Correa Soto, M. Albert Antequera, K. Müller Campos, D. 1 2 4 3 1
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationRadiologic Approach to Smoking Related Interstitial Lung Disease
Radiologic Approach to Smoking Related Interstitial Lung Disease Poster No.: C-1854 Congress: ECR 2013 Type: Educational Exhibit Authors: K.-N. Lee, J.-Y. Han, E.-J. Kang, J. Kang; Busan/KR Keywords: Toxicity,
More informationHypersensitivity Pneumonitis: Spectrum of High-Resolution CT and Pathologic Findings
CT of Hypersensitivity Pneumonitis Chest Imaging Pictorial Essay C. Isabela S. Silva 1 ndrew Churg 2 Nestor L. Müller 1 Silva CIS, Churg, Müller NL Keywords: high-resolution CT, hypersensitivity pneumonitis,
More informationThe crazy-paving pattern: A radiological-pathological correlated and illustrated overview
The crazy-paving pattern: A radiological-pathological correlated and illustrated overview Poster No.: C-0827 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors: W. F. M. De Wever, J. Coolen,
More informationChanges in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation
Eur Respir J 2007; 29: 453 461 DOI: 10.1183/09031936.00015506 CopyrightßERS Journals Ltd 2007 Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after
More informationSpectrum of Cystic Lung Disease and its Mimics. Kathleen Jacobs MD and Elizabeth Weihe MD UC San Diego Medical Center, Department of Radiology
Spectrum of Cystic Lung Disease and its Mimics Kathleen Jacobs MD and Elizabeth Weihe MD UC San Diego Medical Center, Department of Radiology No Financial Disclosures Learning Objectives 1. Review the
More informationFollicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients
Respiratory Medicine (2008) 102, 307 312 Follicular bronchiolitis in surgical lung biopsies: Clinical implications in 12 patients Michelle R. Aerni a, Robert Vassallo a,, Jeffrey L. Myers b, Rebecca M.
More informationCase 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule
HRCT WORK SHOP Case 1 Case 1: Question 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule Case 1: Question 1.2 What is the diagnosis? 1. Hypersensitivity
More informationNew lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma
July 2016 New lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma Contributed by: Laurel Rose, MD, Resident Physician, Indiana University School of Medicine,
More informationImaging Small Airways Diseases: Not Just Air trapping. Eric J. Stern MD University of Washington
Imaging Small Airways Diseases: Not Just Air trapping Eric J. Stern MD University of Washington What we are discussing SAD classification SAD imaging with MDCT emphasis What is a small airway? Airway with
More informationRadiologic-pathologic correlation of pulmonary diseases
The 1578 th Chest Conference/ 3 rd Biennial Clinical- Radiologic-Pathologic Correlation Radiologic-pathologic correlation of pulmonary diseases Harumi Itoh, M.D. University of Fukui, Japan Centriacinar
More informationSilicosis in Turkish denim sandblasters
Occupational Medicine 2006;56:554 558 Published online 4 October 2006 doi:10.1093/occmed/kql094 Silicosis in Turkish denim sandblasters Metin Akgun 1, Arzu Mirici 1, Elif Yilmazel Ucar 1, Mecit Kantarci
More informationAn Image Repository for Chest CT
An Image Repository for Chest CT Francesco Frajoli for the Chest CT in Antibody Deficiency Group An Image Repository for Chest CT he Chest CT in Antibody Deficiency Group is an international and interdisciplinary
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationPulmonary Test Brenda Shinar
Pulmonary Test 2016 Brenda Shinar 1. What is a Renal Tubular Acidosis? What is the difference between the types of RTAs in terms of who gets them and how to diagnose them? Type 1, 2, and 4? Metabolic acidosis
More informationCase Study #2. Case Study #1 cont 9/28/2011. CAPA 2011 Christy Wilson PA C. LH is 78 yowf with PMHx of metz breast CA presents
Case Study #1 CAPA 2011 Christy Wilson PA C 46 yo female presents with community acquired PNA (CAP). Her condition worsened and she was transferred to the ICU and placed on mechanical ventilation. Describe
More informationClinico-Pathologic Conferences Early Bronchus-Associated Lymphoid Tissue Lymphoma Diagnosed with Immunoglobulin Heavy Chain Molecular Testing
Canadian Respiratory Journal Volume 2016, Article ID 7056035, 4 pages http://dx.doi.org/10.1155/2016/7056035 Clinico-Pathologic Conferences Early Bronchus-Associated Lymphoid Tissue Lymphoma Diagnosed
More information10/17/2016. Nuts and Bolts of Thoracic Radiology. Objectives. Techniques
Nuts and Bolts of Thoracic Radiology October 20, 2016 Carleen Risaliti Objectives Understand the basics of chest radiograph Develop a system for interpreting chest radiographs Correctly identify thoracic
More informationT he diagnostic evaluation of a patient with
546 REVIEW SERIES Challenges in pulmonary fibrosis? 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias Michael B Gotway, Michelle M
More informationSCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial
More informationACUTE RESPIRATORY DISTRESS SYNDROME
ACUTE RESPIRATORY DISTRESS SYNDROME Angel Coz MD, FCCP, DCE Assistant Professor of Medicine UCSF Fresno November 4, 2017 No disclosures OBJECTIVES Identify current trends and risk factors of ARDS Describe
More informationInitial presentation of idiopathic pulmonary fibrosis as an acute exacerbation
Respiratory Medicine CME (2008) 1, 43 47 respiratory MEDICINE CME CASE REPORT Initial presentation of idiopathic pulmonary fibrosis as an acute exacerbation Krishna M. Sundar a,b,, Dixie L. Harris a a
More informationCLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)
CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD) David Northrop MBA, RRT Assistant Director of Respiratory Therapy Services The University of Kansas Health System Clinical Assistant
More informationNitrofurantoin Pulmonary Toxicity: A Brief Review
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 6 Number 2 B Vahid, B Wildemore Citation B Vahid, B Wildemore.. The Internet Journal of Pulmonary Medicine. 2005 Volume 6 Number 2. Abstract
More informationPulmonary Sarcoidosis - Radiological Evaluation
Original Research Article Pulmonary Sarcoidosis - Radiological Evaluation Jayesh Shah 1, Darshan Shah 2*, C. Raychaudhuri 3 1 Associate Professor, 2 1 st Year Resident, 3 Professor and HOD Radiology Department,
More informationLangerhans Cell Histiocytosis with Anterior Mediastinum, Pulmonary and Liver Involvement: CT Demonstration
Chin J Radiol 2002; 27: 191-195 191 Langerhans Cell Histiocytosis with Anterior Mediastinum, Pulmonary and Liver Involvement: CT Demonstration SIU-CHEUNG CHAN 1 MUN-CHING WONG 1 SHIU-FENG HUANG 2 WAN-CHAK
More informationChest radiograph of an. asymptomatic man. Case report. Case history
Eleftheria Chaini 1, Niki Giannakou 2, Dimitra Haini 3, Anna Maria Athanassiadou 4, Angelos Tsipis 4, Nikolaos D. Hainis 5 elhaini@otenet.gr 1 Pulmonary Dept, Corfu General Hospital, Kontokali, Greece.
More informationCase Report Langerhans Cell Histiocytosis Presenting as Uncontrolled Asthma
Case Reports in Medicine Volume 2013, Article ID 637232, 4 pages http://dx.doi.org/10.1155/2013/637232 Case Report Langerhans Cell Histiocytosis Presenting as Uncontrolled Asthma Frederic A. Rawlins III,
More informationThoracic sarcoidosis: Pictoral review of typical and atypical findings
Thoracic sarcoidosis: Pictoral review of typical and atypical findings Poster No.: C-0804 Congress: ECR 2010 Type: Educational Exhibit Topic: Chest Authors: A. Ferreira, J. Calha; Lisbon/PT Keywords: Sarcoidosis,
More informationPulmonary Manifestations Of Skeletal Disorders
Pulmonary Manifestations Of Skeletal Disorders U. A. Saeed, MBBS FCPS, J. Nair, MBBS MD, R. Khosla, MD FRCR, K. Sayegh, MD FRCPC, J. Kosiuk, MD FRCPC, J. Taylor, MD FRCPC; Department of Radiology, McGill
More informationClinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease
Thorax 1999;54:1009 1014 1009 James Moon, Ronald M du Bois, Thomas V Colby, David M Hansell, Andrew G Nicholson Interstitial Lung Disease Unit J Moon R M du Bois Department of Radiology D M Hansell Department
More informationA Rare Case of Lymphangioleiomyomatosis in Sri Lanka
A Rare Case of Lymphangioleiomyomatosis in Sri Lanka Author s Details: (1) Dushantha Madegedara (2) Asela Rasika Bandara (3) Sachini Seneviratne (4) Samadara Nakandala (5) Rathnayake R.M.D.H.M - (1) (2)
More informationCLINICAL VIGNETTE Sarcoidosis: A Case Study Gloria Kim, M.D.
CLINICAL VIGNETTE Sarcoidosis: A Case Study Gloria Kim, M.D. Case Report A 56-year-old female presented to her primary care physician with complaints of dyspnea on exertion and increasing cough. She reported
More informationImaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung
Imaging of cardio-pulmonary treatment related damage Dr. Andrea Borghesi Dr. Emanuele Gavazzi Department of Radiology 2 University of Brescia Radiotheraphy and Lung The goal of radiation therapy (RT) is
More informationRadiologists toolbox to differentiate alveolar versus interstitial lung diseases
Radiologists toolbox to differentiate alveolar versus interstitial lung diseases Dr Sumer Shikhare, Dr Trishna Shimpi, Dr Ashish Chawla Khoo Teck Puat Hospital Singapore. Relevant financial disclosures
More informationPulmonary veno-occlusive disease
Disclosure Objectives Pulmonary veno-occlusive disease Tilman Humpl The Hospital for Sick Children University of Toronto, Canada Advisor/Research Grants Actelion Pfizer Historical aspects Epidemiology/Genetics
More informationCareful histopathological evaluation has shown the traditionally clinical diagnosis of
Demystifying Idiopathic Interstitial Pneumonia Harold R. Collard, MD; Talmadge E. King, Jr, MD REVIEW ARTICLE Careful histopathological evaluation has shown the traditionally clinical diagnosis of idiopathic
More informationReceived February 23, Received revised March 15, Accepted for publication March 16, University of California, Davis, CA, USA
643990HICXXX10.1177/2324709616643990Journal of Investigative Medicine High Impact Case ReportsNguyen et al case-report2016 Case Report Acute Fibrinous and Organizing Pneumonia Associated With Allogenic
More informationFocal Organizing Pneumonia on Surgical Lung Biopsy* Causes, Clinicoradiologic Features, and Outcomes
CHEST Focal Organizing Pneumonia on Surgical Lung Biopsy* Causes, Clinicoradiologic Features, and Outcomes Fabien Maldonado, MD; Craig E. Daniels, MD; Elizabeth A. Hoffman, MD; Eunhee S. Yi, MD; and Jay
More informationThe Imaging Analysis of Pulmonary Sarcodiosis
www.cancercellresearch.org ISSN: 2161-2609 Article The Imaging Analysis of Pulmonary Sarcodiosis Xin He, Chuanyu Zhang* Department of Radiology, Affiliated Hospital of Qingdao University, Qingdao, China
More informationPleuroparenchymal fibroelastosis as a late complication of chemotherapy agents
AGORA RESEARCH LETTERS Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents To the Editor: We identified six patients with clinical, radiographic and physiological features typical
More informationAn Introduction to Radiology for TB Nurses
An Introduction to Radiology for TB Nurses Garold O. Minns, MD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Garold O. Minns, MD has the following disclosures
More informationThe Pulmonary Pathology of Iatrogenic Immunosuppression. Kevin O. Leslie, M.D. Mayo Clinic Scottsdale
The Pulmonary Pathology of Iatrogenic Immunosuppression Kevin O. Leslie, M.D. Mayo Clinic Scottsdale The indications for iatrogenic immunosuppression Autoimmune/inflammatory disease Chemotherapy for malignant
More informationPULMONARY TUBERCULOSIS RADIOLOGY
PULMONARY TUBERCULOSIS RADIOLOGY RADIOLOGICAL MODALITIES Medical radiophotography Radiography Fluoroscopy Linear (conventional) tomography Computed tomography Pulmonary angiography, bronchography Ultrasonography,
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationNeurofibromatosis-associated lung disease: a case series and literature review
Eur Respir J 2007; 29: 210 214 DOI: 10.1183/09031936.06.00044006 CopyrightßERS Journals Ltd 2007 CASE STUDY Neurofibromatosis-associated lung disease: a case series and literature review A.C. Zamora*,#,+,
More informationCase 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random
Interesting case Case 1 Case 1 : Question 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random Case 1: Answer 1.1 What is the intralobular distribution? 1. Centrilobular
More informationTB Radiology for Nurses Garold O. Minns, MD
TB Nurse Case Management Salina, Kansas March 31-April 1, 2010 TB Radiology for Nurses Garold O. Minns, MD April 1, 2010 TB Radiology for Nurses Highway Patrol Training Center Salina, KS April 1, 2010
More informationEosinophils and effusion: a clinical conundrum
Ruth Sobala, Kevin Conroy, Hilary Tedd, Salem Elarbi kevin.peter.conroy@gmail.com Respiratory Dept, Queen Elizabeth Hospital, Gateshead, UK. Eosinophils and effusion: a clinical conundrum Case report A
More informationSerial computed tomographic evaluation in desquamative interstitial pneumonia
Thorax 1997;52:333 337 333 Serial computed tomographic evaluation in desquamative interstitial pneumonia Masanori Akira, Satoru Yamamoto, Hideki Hara, Mitsunori Sakatani, Einosuke Ueda Abstract a better
More informationAtopic Pulmonary Disease: Findings on Thoracic Imaging
July 2003 Atopic Pulmonary Disease: Findings on Thoracic Imaging Rebecca G. Breslow Harvard Medical School Year IV Churg-Strauss Syndrome Hypersensitivity Pneumonitis Asthma Atopic Pulmonary Disease Allergic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationIdiopathic interstitial pneumonias (IIPs) are a group of
SYMPOSIA C. Isabela S. Silva, MD, PhD and Nestor L. Müller, MD, PhD Abstract: The idiopathic interstitial pneumonias (IIPs) are a group of diffuse parenchymal lung diseases of unknown etiology characterized
More information